BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3K malignancies.
BBOT has raised $200.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2024.
BBOT's investors include Wellington Management, Deerfield Management, Cormorant Asset Management, Omega Funds, Longwood Fund.
BBOT is headquartered in Palo Alto, United States.
BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3K malignancies.
BBOT is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BBOT — Funding & Investors." VCBacked, May 2, 2024, https://www.vcbacked.co/company/bbot-palo-alto. Accessed October 21, 2026.
VCBacked. (2024). BBOT — Funding & Investors. Retrieved October 21, 2026, from https://www.vcbacked.co/company/bbot-palo-alto
{{cite web |title=BBOT — Funding & Investors |url=https://www.vcbacked.co/company/bbot-palo-alto |website=VCBacked |access-date=October 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated